Grant: Engage Grants Program
University of British Columbia
$25,000.00
Synthesis of hydroxyadamantanacetamide derivatives for the development of novel biomarkers
EF 2012-13
Résumé
Cancer ranks among the top leading causes of death in Canada. Approximately 42% of the Canadian
population develops malignant tumors over their lifetime and 25% of the population is predicted to die as a
result of cancer. The early detection of malignant tumor growth is critical for increasing survival rates.
BioMark, a Canadian based medical technology company, focuses on developing new assays for early tumor
detection. They have recently developed and commercialized an exciting new cancer diagnostic, the
Acetylated Biomarker Assay (ABA) Red Alert technology. This assay detects spermine/spermidine
N-acetyltransferase (SSAT), an enzyme that is up-regulated in solid tumors. Despite this exciting
breakthrough, the technology is very expensive. BioMark is currently developing a significantly more cost
effective in vitro diagnostic kit using monoclonal antibodies. Key for this project's success is the synthesis of
gram quantities of two different hydroxyadamantanacetamide derivatives are required to establish a better
antibody with high specificity. The desired chemicals are only available through custom synthesis and are,
thus, prohibitively expensive. Furthermore, currently synthetic routes in the literature are highly inefficient.
The goal of this project is to develop a concise and modular synthetic route to hydroxyadamantanacetamide
derivatives that can be readily scalable. This will provide sufficient material for BioMark to explore the use of
these compounds in the production of highly selective monoclonal antibodies for early tumor detection.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
429903-2012
Name nom
Sammis, Glenn
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthesis of hydroxyadamantanacetamide derivatives for the development of novel biomarkers
Keyword
NSERC
Application summary
Cancer ranks among the top leading causes of death in Canada. Approximately 42% of the Canadian
population develops malignant tumors over their lifetime and 25% of the population is predicted to die as a
result of cancer. The early detection of malignant tumor growth is critical for increasing survival rates.
BioMark, a Canadian based medical technology company, focuses on developing new assays for early tumor
detection. They have recently developed and commercialized an exciting new cancer diagnostic, the
Acetylated Biomarker Assay (ABA) Red Alert technology. This assay detects spermine/spermidine
N-acetyltransferase (SSAT), an enzyme that is up-regulated in solid tumors. Despite this exciting
breakthrough, the technology is very expensive. BioMark is currently developing a significantly more cost
effective in vitro diagnostic kit using monoclonal antibodies. Key for this project's success is the synthesis of
gram quantities of two different hydroxyadamantanacetamide derivatives are required to establish a better
antibody with high specificity. The desired chemicals are only available through custom synthesis and are,
thus, prohibitively expensive. Furthermore, currently synthetic routes in the literature are highly inefficient.
The goal of this project is to develop a concise and modular synthetic route to hydroxyadamantanacetamide
derivatives that can be readily scalable. This will provide sufficient material for BioMark to explore the use of
these compounds in the production of highly selective monoclonal antibodies for early tumor detection.